Kirin Company
Search results
The Kyowa Kirin Group is a Japanese pharma group that develops innovative specialty drugs, to raise the health and well-being of people around the world. Its flagship business Kyowa Kirin Co., Ltd. creates antibody-based drugs for cancer, kidney disease, and immune system diseases.
Jan 1, 2024 · Kyowa Kirin R&D Meeting. September 26, 2024. Online Meeting Presentation （3,155KB）. This document is used only for the purpose of providing the information to investors. Though it may contain the information concerning pharmaceutical products (including products under development), it is not for the purpose of promotion, advertising, or ...
In his current role as the Senior Vice President of Global Clinical Operations for Kyowa Kirin, Inc. Dr. Katz plays a vital role in shaping the strategic and operating framework of Kyowa Kirin’s broad global clinical development program within the Global Development Organization.
“I am very excited to announce that Kyowa Kirin decided to construct a new manufacturing plant for biologics drug substance in the United States,” said Toshiyuki Kurata, Chief Supply Chain Officer, and Global Manufacturing Head at Kyowa Kirin. “The new facility will be scalable
Kyowa Kirin pursues scientific breakthroughs to address unmet clinical needs. Learn more about our portfolio of specialty medicines in nephrology, oncology, immunology & allergy, and neurology. Join us to grow your career or partner with us to propel your research discoveries into the hands of patients and physicians.
At Kyowa Kirin, helping patients is our business. Kyowa Kirin is a global specialty pharmaceutical company. Every day, we aspire to make a profound impact on patient’s lives through our work, our people, and our collaborations – all guided by our values. We work on diseases where the need for a new treatment is high.
Sep 25, 2024 · Tokyo, Japan, September 25, 2024-- Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151, President and CEO: Masashi Miyamoto) announced top-line results of the Phase 3 ROCKET HORIZON trial of rocatinlimab, an investigational therapy targeting the OX40 receptor.
Jan 1, 2024 · January 1, 2022 - December 31, 2022. Fiscal Year. Consolidated Financial Summary (IFRS) Fiscal 2022 （818KB）. Appendix to the Consolidated Financial Summary Fiscal 2022 （1,443KB）. Results Presentation Fiscal 2022 （1,118KB）. Transcript of Results Briefing Fiscal 2022 （2,974KB）. Revenues from other products （27KB）.
The Kyowa Kirin Group is a Japanese pharma group that develops innovative specialty drugs, to raise the health and well-being of people around the world. Since the early 2000s, Kyowa Kirin has been present in Malaysia with our innovative medicines designed to alleviate suffering and restore health to patients.
Kyowa Kirin strives to create and deliver novel medicines with life-changing value. Learn about our innovative medicines that are available in Canada. Our Medicines
